HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Figures Only Full Text Full Text (PDF) Correspondence: Submit a response Alert me when this article is cited Alert me when Correspondence are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by del Zoppo, G. J. Search for Related Content PubMed PubMed Citation Articles by del Zoppo, G. J.

The role of platelets in ischemic stroke

From the Department of Molecular and Experimental Medicine, the Scripps Research Institute, and the Division of Hematology/Medical Oncology, Scripps Clinic and Research Foundation, La Jolla, CA.

Address correspondence and reprint requests to Dr. Gregory J. del Zoppo, Department of Molecular and Experimental Medicine, Scripps Clinic and Research Foundation, 10550 North Torrey Pines Road, SBR-17, La Jolla, CA 92037.

Abstract.

Platelets have assumed a role in the development of focal cerebral ischemia by virtue of their participation in thromboemboli that may initiate stroke symptoms. Platelets are one component of the blood-vascular axis responsible for preventing hemorrhage. Activated platelets initiate hemostatic plug formation and provide a scaffolding for coagulation activation. Platelets are activated by a number of stimuli, such as exposure of the vascular subendothelium, fibrin deposition, and abnormal surfaces, e.g., atheromata. A number of observations, including the appearance of platelet thrombi on atheromata in situ, indicate that platelet physiology is relevant to stroke. In addition, certain antiplatelet agents (e.g., aspirin) significantly reduce the incidence of ischemic stroke after initial transient ischemic attacks. Aspirin, the combination of aspirin and dipyridamole, and ticlopidine have all been shown to be useful in reducing the frequency of secondary stroke events. Clopidogrel has been shown to reduce the frequency of secondary vascular ischemic events when stroke, myocardial infarction, and peripheral arterial disease are considered together. Unfortunately, all antithrombotic agents carry a potential risk for inducing symptomatic intracerebral hemorrhage during ischemic stroke. The mechanism by which this may happen with antiplatelet agents has not yet been determined. As in other areas of stroke treatment, it is the balance between efficacy in reduction of symptomatic thrombotic events and the risk for hemorrhage that will define benefit.

This article has been cited by other articles:

				K. Qian, F. Xie, A. W. Gibson, J. C. Edberg, R. P. Kimberly, and J. Wu Functional expression of IgA receptor Fc{alpha}RI on human platelets J. Leukoc. Biol., December 1, 2008; 84(6): 1492 - 1500. [Abstract] [Full Text] [PDF]

				G. Stoll, C. Kleinschnitz, and B. Nieswandt Molecular mechanisms of thrombus formation in ischemic stroke: novel insights and targets for treatment Blood, November 1, 2008; 112(9): 3555 - 3562. [Abstract] [Full Text] [PDF]

				C. Kleinschnitz, M. Pozgajova, M. Pham, M. Bendszus, B. Nieswandt, and G. Stoll Targeting Platelets in Acute Experimental Stroke: Impact of Glycoprotein Ib, VI, and IIb/IIIa Blockade on Infarct Size, Functional Outcome, and Intracranial Bleeding Circulation, May 1, 2007; 115(17): 2323 - 2330. [Abstract] [Full Text] [PDF]

				V. Wolff, B. Aleil, M. Giroud, J.-L. Lorenzini, N. Meyer, M.-L. Wiesel, J.-P. Cazenave, and F. Lanza Soluble Platelet Glycoprotein V Is a Marker of Thrombosis in Patients With Ischemic Stroke Stroke, March 1, 2005; 36(3): e17 - e19. [Abstract] [Full Text] [PDF]

				P. Bath, C. Algert, N. Chapman, B. Neal, and for the PROGRESS Collaborative Group Association of Mean Platelet Volume With Risk of Stroke Among 3134 Individuals With History of Cerebrovascular Disease Stroke, March 1, 2004; 35(3): 622 - 626. [Abstract] [Full Text] [PDF]

				R. J. Hansen and J. P. Balthasar Effects of intravenous immunoglobulin on platelet count and antiplatelet antibody disposition in a rat model of immune thrombocytopenia Blood, August 28, 2002; 100(6): 2087 - 2093. [Abstract] [Full Text] [PDF]

				D. T. Neilipovitz, G. L. Bryson, and G. Nichol The Effect of Perioperative Aspirin Therapy in Peripheral Vascular Surgery: A Decision Analysis Anesth. Analg., September 1, 2001; 93(3): 573 - 580. [Abstract] [Full Text] [PDF]

				R. I. Baker, J. Eikelboom, E. Lofthouse, N. Staples, V. Afshar-Kharghan, J. A. Lopez, Y. Shen, M. C. Berndt, and G. Hankey Platelet glycoprotein Ib{alpha} Kozak polymorphism is associated with an increased risk of ischemic stroke Blood, July 1, 2001; 98(1): 36 - 40. [Abstract] [Full Text] [PDF]

				G. Agnelli Rationale for the use of platelet aggregation inhibitors in PAD patients Vascular Medicine, February 1, 2001; 6(1_suppl): 13 - 15. [Abstract] [PDF]

				P. D. Schellinger, E. Schmutzhard, J. B. Fiebach, B. Pfausler, H. Maier, and S. Schwab Poliomyelitic-like illness in central European encephalitis Neurology, July 25, 2000; 55(2): 299 - 302. [Abstract] [Full Text] [PDF]

				W.-L. van der Pol, L. H. van den Berg, R. H. M. Scheepers, J. G. van der Bom, P. A. van Doorn, R. van Koningsveld, M. C. L. van den Broek, J. H. J. Wokke, and J. G. J. van de Winkel IgG receptor IIa alleles determine susceptibility and severity of Guillain-Barre syndrome Neurology, April 25, 2000; 54(8): 1661 - 1665. [Abstract] [Full Text] [PDF]